Targeting the proliferation of glioblastoma cells and enhancement of doxorubicin and temozolomide cytotoxicity through inhibition of PFKFB4 and HMOX1 genes with siRNAs

Abstract Glioblastoma multiforme continues to be one of the most aggressive brain cancers, posing a serious health challenge, as it offers a median survival of only 15–23 months and a 5-year survival rate of less than 6%. Current treatments often prove inadequate, underscoring the urgency for new th...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Hamzeh J. Al-Ameer, Malek Zihlif, Ahmed Maslat, Wajdy J. Al-Awaida, Amani Marwan Ayyash, Amer Imraish, Nidal Al-Qinna, Tareq Al-Omari, Talal Al-Qaisi, Walid Al-Zyoud, Bayan T. Alzubi, Ali M. Atoom, Isam A. Fattash, Shubhankar Ambike, Khang Wen Goh, Yulia Sh. Gushchina
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Nature Portfolio 2025-07-01
Rangatū:	Scientific Reports
Ngā marau:	Glioblastoma siRNA PFKFB4 HMOX1 Doxorubicin Temozolomide
Urunga tuihono:	https://doi.org/10.1038/s41598-025-97192-z
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!